At present, the dual anti-HER2 therapy with TP and docetaxel/paclitaxel is the first line of treatment for HER2 positive metastatic or recurrent breast cancer according to the National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2023 [10]. The gene discussed is ERBB2; the disease is breast carcinoma.